Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Retained Earnings (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Retained Earnings data on record, last reported at $642.5 million in Q3 2025.

  • For Q3 2025, Retained Earnings rose 7383.2% year-over-year to $642.5 million; the TTM value through Sep 2025 reached $642.5 million, up 7383.2%, while the annual FY2024 figure was $568.8 million, 6808.98% up from the prior year.
  • Retained Earnings reached $642.5 million in Q3 2025 per AMPH's latest filing, up from -$5.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $642.5 million in Q3 2025 and bottomed at -$8.8 million in Q2 2024.
  • Average Retained Earnings over 5 years is $187.9 million, with a median of $130.6 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: crashed 103.75% in 2023, then soared 7383.2% in 2025.
  • A 5-year view of Retained Earnings shows it stood at -$6.8 million in 2021, then dropped by 27.48% to -$8.6 million in 2022, then increased by 1.69% to -$8.5 million in 2023, then surged by 6808.98% to $568.8 million in 2024, then increased by 12.95% to $642.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were $642.5 million in Q3 2025, -$5.4 million in Q2 2025, and $594.1 million in Q1 2025.